NCT00459862 · OUTCOME

Determine the Clinical Toxicities of This Drug in This Participant Population.

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma · Source last updated 2015-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Participants will be evaluated every cycle during treatment

What was measured

The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.

Analysis population: All 34 participants were evaluable for adverse events.

Groups in this outcome

Arm I

Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	34

Reported measurements

Grade 3 or Higher

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I	23	Not reported	Not reported	Not reported	Not reported

Grade 4 or Higher

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I	5	Not reported	Not reported	Not reported	Not reported

Grade 5

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
23
title
Grade 3 or Higher
categories
measurements
group Id
OG000
value
5
title
Grade 4 or Higher
categories
measurements
group Id
OG000
value
3
title
Grade 5

denoms

counts
group Id
OG000
value
34
units
Participants

description

The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.

groups

description
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Arm I

param Type

NUMBER

population Description

All 34 participants were evaluable for adverse events.

reporting Status

POSTED

time Frame

Participants will be evaluated every cycle during treatment

title

Determine the Clinical Toxicities of This Drug in This Participant Population.

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice